Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.

Authors

Jaleh Fallah

Jaleh Fallah

U.S. Food and Drug Administration, Silver Spring, MD

Jaleh Fallah , Haley Gittleman , Chana Weinstock , Erik Bloomquist , Elaine Chang , Daniel L. Suzman , Sundeep Agrawal , Amna Ibrahim , Shenghui Tang , Richard Pazdur , Julia A. Beaver , Laleh Amiri-Kordestani

Organizations

U.S. Food and Drug Administration, Silver Spring, MD

Research Funding

No funding received
None

Background: Immunotherapy-based combination therapies (IO-X) are standard of care for metastatic RCC (mRCC) in the frontline setting. Limited data is available on the role of cytoreductive nephrectomy prior to IO-X in patients (pts) with mRCC (Bakouny, et al. GU ASCO 2020). We assessed the correlation between nephrectomy prior to IO-X and overall survival (OS) in pts with de novo mRCC. Methods: We pooled data from trials submitted for FDA review of a checkpoint inhibitor combination as first-line treatment for pts with mRCC. We only included trials with available data for stage at initial diagnosis (dx) to identify pts with stage IV disease at initial dx and to exclude those with nephrectomy in the non-metastatic setting. Kaplan-Meier method was used to estimate median OS in pts with de novo mRCC with and without nephrectomy prior to IO-X. Results: Five trials met inclusion criteria, all of which evaluated IO in combination with a kinase inhibitor. Data for stage at initial dx was available in 1708 pts who received IO-X. The majority of pts were male (72%) and White (80%). Among the 849 pts (50%) with stage IV RCC at initial dx, 523 pts (62%) had nephrectomy prior to IO-X. All pts had clear cell histology; Sarcomatoid differentiation was present in tumor pathology of 25% and 10% of pts with and without prior nephrectomy, respectively. Proportion of pts with favorable, intermediate and poor risk disease was 10%, 70% and 20%, respectively. OS appeared better in those with stage IV disease at dx who had prior nephrectomy compared to pts without nephrectomy (Hazard ratio (HR) = 0.53, 95% CI: 0.42, 0.68), even after adjusting for age and prognostic risk group (HR = 0.59, 95% CI: 0.46, 0.75) (see table). Conclusions: In this retrospective exploratory analysis, nephrectomy prior to IO-X in pts with new dx of stage IV RCC appeared to be associated with improved OS, even when controlling for age and prognostic risk group. The decision for nephrectomy is affected by factors such as medical comorbidities which could not be completely controlled. Results should be considered hypothesis generating.

Pts with stage IV RCC at initial dx (N = 849)
Prior Nephrectomy (N = 523)
No Prior Nephrectomy (N = 326)
HR (95% CI)
Age, mean (SD)
59.8 (9.3)
62.3 (10.3)

Months from diagnosis to randomization,  median (IQR)
3.4 (1.9, 8.0)
1.5 (1.0, 2.5)

Death events N (%)
139/523 (27%)
134/326 (41%)

Favorable risk
9/44 (20%)
10/37 (27%)
0.69 (0.28, 1.72)
Intermediate risk
93/397 (23%)
80/200 (40%)
0.47 (0.35, 0.64)
Poor risk
37/82 (45%)
44/87 (51%)
0.84 (0.54, 1.30)
Median OS (unadjusted HR)
NR (31.8, NR)
24.5 (19.6, NR)
0.53 (0.42, 0.68)
Median OS (HR adjusted for age and prognostic  risk group)
NR (31.8, NR)
25.2 (19.8, NR)
0.59 (0.46, 0.75)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4516)

DOI

10.1200/JCO.2021.39.15_suppl.4516

Abstract #

4516

Abstract Disclosures